Lake Street Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $8
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Lake Street analyst Frank Takkinen maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $10 to $8.
Lake Street analyst Frank Takkinen maintains TriSalus Life Sciences (NASDAQ:TLSI) with a Buy and lowers the price target from $10 to $8.